---
title: ACS
layout: diseases
author: Corbin Cox
last-updated: 2018-12-3
created: 2018-12-3
toc: true
common: true
---

# Dx [^tintinalli]<sup>,</sup>[^amsterdam2014]

-   **ECG w/i 10min of arrival, then Q15-30min x1hr if not initially
    diagnositc**
-   CXR / Chest CT to r/o thoracic aortic aneurysm / dissection, PE, pneumothorax, PNA, etc
-   Serial cTn ASAP then Q3-6hr
-   [TIMI Risk Score](https://qxmd.com/calculate/calculator_168/timi-risk-score-nstemi) for all NSTE-ACS (1pt for each below [^dipiro])
    -   &ge; 65yo
    -   Prior Coronary Stenosis &ge; 50%
    -   ST Depression &ge; 0.5mm
    -   &ge; 2 Anginal events w/i 24hrs
    -   ASA use w/i 7d
    -   (+) Cardiac Enzymes
    -   &ge; 3 CAD risk factors
        -   Smoking
        -   HTN
        -   Dyslipidemia
        -   DM
        -   FHx of premature CAD or Sudden Cardiac Death
    -   [GRACE Risk Score](https://qxmd.com/calculate/calculator_262/grace)

## STEMI Dx Criteria

-   ESC/ACC/AHA [^ogara2013]<sup>,</sup>[^thygesen]
    -   ST Elevation in 2 anatomically contiguous leads &ge; 0.1mV at the J-point except V<sub>2</sub>-V<sub>3</sub> (use the following in V<sub>2</sub>-V<sub>3</sub>
    -   Men &ge; 40: &ge; 0.2 mV
    -   Men &lt; 40: &ge; 0.25 mV
    -   Women: &ge; 0.15 mV
    -   New horizontal / down-sloping ST-depression in 2 contiguous leads &ge; 0.05 mV
    -   T-wave Inversion in 2 contiguous leads &ge; 0.1 mV with prominent R waves or $$\frac{R}{S} > 1$$
    -   Definitively new LBBB
-   In the presence of existing LBBB consider Smith-Modified Sgarbossa
    Criteria [^smith2012-lbbb-stemi]
    -   &ge; 3 points &rArr; 98% Likelihood of MI
    -   ST-elevation ≥1 mm in a lead with upward QRS complex (concordant) - 5 points
    -   ST-depression ≥1 mm in lead V1, V2, or V3 - 3 points
    -   $$\frac{\text{ST-change}}{\text{S-wave}} \le -0.25$$ - 2 points
-   New LAFB and RBBB is concerning for LAD occlusion
-   ST-elevation with ST-depression in aVL is highly suspicious for STEMI
-   Local ST-depression in V<sub>1</sub>-V<sub>4</sub> is suspicious for isolated posterior infarct
-   ST-elevation in aVL with depression in III is suspicious for high lateral MI
-   Subtle LAD occlusion vs EBR [^driver2017]
    -   0.052 x QTc - 0.151 x (QRS voltage in V2) - 0.268 x (R-wave amplitude in V4) + 1.062 x (ST-elevation 60ms after J-point in V3)
    -   &ge; 18.2 &rArr; 88.8% sensitive, 94.7% specific
    -   &ge; 17.75 &rArr; 90.2% sensitive, 90.6% specific

Infarction EKG Patterns [^tintinalli]
{: .caption}

|Location|Electrocardiographic Findings|Artery|
|---|---|---|
|Anteroseptal|ST-segment elevations in V1, V2, and possibly, V3|LAD|
|Anterior|ST-segment elevations in V1, V2, V3, and V4|LAD|
|Anterolateral|ST-segment elevations in V1--V6, I, and aVL|LAD or LCX|
|Lateral|ST-segment elevations in I and aVL|LCX|
|Inferior|ST-segment elevations in II, III, and aVF|RCA or RCX (20%)|
|Inferolateral|ST-segment elevations in II, III, aVF, and V5 and V6|LCX or RCA or RCX|
|True posterior|Initial R waves in V1 and V2 &gt; 0.04 s and R/S ratio &ge; 1|LCX|
|Right ventricular|ST-segment elevations in II, III, and aVF and ST elevation in right-side V4|RCA|

# Tx [^tintinalli]<sup>,</sup>[^ogara2013]

-   Empiric ASA 325mg (chew & swallow) for all pts at risk for AMI w/o CIs
-   Nitrates
    -   Nitro 0.4mg SL Q5min x3 doses
    -   Nitro IV Start at 10 mcg/min, titrate to 10% reduction in MAP if normotensive, 30% reduction in MAP if hypertensive
    -   Avoid in RV infarction (d/t dependance on preload for maintaining CO)
    -   CI w/ PDE-5 Inhibitors w/i 24hr (48hr if Tadalafil)
-   Supplemental O2 PRN for O2Sat &lt; 90%
-   Morphine 2-5mg IV Q5-15min PRN is the preferred method of pain control d/t vasodilatory properties

## STEMI [^tintinalli]<sup>,</sup>[^ogara2013]

### PCI Management

-   PCI w/i 90min if PCI at facility or w/i 120min for transfer if\...
    -   &lt;12hr from SSx onset
    -   &lt;12h and CI to fibrinolytics regardless of time limits above
    -   Cardiogenic shock or acute HF regardless of SSx onset
    -   Potentially if SSx for 12-24hr
-   P2Y12 Inhibitor
    -   Clopidogrel 600mg load then 75mg PO QD x1yr
    -   Prasugrel 60mg load then 10mg PO QD x1yr (CI w/ prior stroke)
    -   Ticagrelor 180mg load then 90mg PO BID x1yr (**ASA NTE 100mg w/ ticagrelor**)
-   Anticoag
    -   UFH w/ GP IIb/IIIa: 50-70 U/kg bolus targeting aPTT 200-250s
    -   UFH w/o GP IIB/IIIA: 70-100 U/kg bolus targeting aPTT 250-350s
    -   Bivalirudin 0.75 mg/kg bolus then 1.75 mg/kg/hr
        -   Reduce to 1 mg/kg/hr if CrCl &lt; 30
        -   Preferred over UFH w/ GP IIb/IIIa if high bleed risk
-   GP IIb/IIIa Inhibitors
    -   Only for select patients
    -   Abciximab 0.25 mg/kg IVB then 0.125 mcg/kg/min NTE 10 mcg/min
    -   Tirofiban 25 mcg/kg IVB then 0.15 mcg/kg/min
        -   CrCl &lt; 30: Reduce rate by 50%
    -   Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min then 180 mcg/kg IVB 10min after 1st IVB
        -   CrCl &lt; 50: Reduce rate by 50%
        -   Avoid in pts on HD

### Medical Management

-   Thrombolytics preferably w/i 30min, should be w/i 1-2hr of presentation if PCI not indicated from above (see dosing below)
    -   SSx &lt; 12h
    -   Potentially if SSx for 12-24hr
    -   Check All CIs to thrombolytics closely
-   Clopidogrel
    -   &le; 75yo: 300mg load then 75mg QD x14d-1yr
    -   &gt; 75yo: 75mg QD x14d-1yr (no load)
-   Anticoag
    -   UFH
        -   Target aPTT 1.5-2x ULN (&rArr; 50-70s) x48hr or until revascularization
        -   60 U/kg IVB NTE 4000 U then
        -   12 U/kg/hr NTE 1000 U/hr initially titrated to above goal
    -   Enoxaparin
        -   &lt; 75yo: 30mg **IV** then 15min later 1 mg/kg SubQ Q12H NTE 100mg for the 1st 2 doses
        -   &ge; 75yo: 0.75 mg/kg SubQ Q12H NTE 75mg for the 1st 2 doses
        -   CrCl &lt; 30: 1 mg/kg Q24H instead
        -   For duration of stay NTE 8d or until revascularization (unless other indication arises)
    -   Fondaparinux
        -   2.5mg IVB then 2.5mg SubQ QD starting the next day
        -   CI if CrCl &lt; 30
        -   For duration of stay NTE 8d or until revascularization (unless other indication arises)

## NSTE-ACS [^amsterdam2014]

### Choosing Strategies

**Early Invasive w/i 2hr**

-   Refractory Angina
-   Hemodynamic / Electrical Instability
-   Sustained VT / VF
-   SSx of HF or mitral regurgitation
-   Stable pts w/ increased risk of clinical events
-   Early-invasive (&lt; 24hr) is better than delayed-invasive if intermediate-high risk

**Ischemia Guided**

-   Extensive co-morbidities significantly increasing the risk of catheterization
-   Acute chest-pain that has a low likelihood of being ACS who are (-) troponin, esp. in women
-   TIMI 0-1 or Grace &lt; 109
-   Pt / clinician preference in pts w/o high-risk features

**Early Invasive w/i 24hr**

-   None of above but GRACE &gt; 140
-   Changes in Troponin
-   New ST depression

**Delayed Invasive (25-72hr)**

-   None of above but DM
-   CrCl &lt; 60
-   LVEF &lt; 40%
-   PCI w/i 6mo
-   Prior CABG
-   GRACE 109-140 or TIMI &ge; 2
-   Early postinfarction angina

### Ischemia Guided Strategy

-   P2Y12 Inhibitor
    -   Clopidogrel 600mg load then 75mg PO QD x1yr
    -   Ticagrelor 180mg load then 90mg PO BID x1yr (**ASA NTE 100mg w/ ticagrelor**, preferred)
-   Anticoag
    -   UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI
    -   Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI
    -   Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI

### Early-Invasive Strategy

-   P2Y12 Inhibitor
    -   Clopidogrel 600mg load then 75mg PO QD x1yr
    -   Ticagrelor 180mg load then 90mg PO BID x1yr (**ASA NTE 100mg w/ ticagrelor**, preferred)
-   Anticoag
    -   UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI
    -   Bivalirudin 0.1 mg/kg bolus then 0.25 mg/kg/hr
    -   Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI
    -   Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI
-   GP IIb/IIIa Inhibitors (high-risk only)
    -   Only for select patients
    -   Tirofiban 12 mcg/kg IVB then 0.14 mcg/kg/min
        -   CrCl &lt; 30: Reduce rate and bolus by 50%
    -   Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min
        -   CrCl &lt; 50: Reduce rate by 50%
        -   Avoid in pts on HD

## Thrombolytic Dosing [^lexi]

-   tPA
    -   15mg IVB over 1-2min then
    -   0.75mg/kg IV over 30min NTE 50mg then
    -   0.5 mg/kg IV over 1hr NTE 35mg
    -   Total dose NTE 100mg
    -   Wt to achieve max dose: 67kg
-   Reteplase 10 Units IV over 2min then 10 Units IV over 2min 30min later
-   Tenecteplase IV bolus over 5 seconds
    -   &lt;60 kg: 30 mg
    -   &ge; 60 to &lt;70 kg: 35 mg
    -   &ge; 70 to &lt;80 kg: 40 mg
    -   &ge; 80 to &lt;90 kg: 45 mg
    -   &ge; 90 kg: 50 mg

## Thrombolytic CIs [^ogara2013]

**Absolute CIs**

-   Any prior ICH
-   Known structural cerebral vascular lesion (e.g., arteriovenous malformation)
-   Known malignant intracranial neoplasm (primary or metastatic)
-   Ischemic stroke within 3 mo
-   EXCEPT acute ischemic stroke within 4.5 h
-   Suspected aortic dissection
-   Active bleeding or bleeding diathesis (excluding menses)
-   Significant closed-head or facial trauma within 3 mo
-   Intracranial or intraspinal surgery within 2 mo
-   Severe uncontrolled hypertension (unresponsive to emergency therapy)
-   For streptokinase, prior treatment within the previous 6 mo

**Relative CIs**

-   History of chronic, severe, poorly controlled hypertension
-   Significant hypertension on presentation (SBP &gt; 􏰁180 mm Hg or DBP &gt; 􏰁110 mm Hg)
-   History of prior ischemic stroke &gt; 􏰁3 mo
-   Dementia
-   Known intracranial pathology not covered in absolute contraindications
-   Traumatic or prolonged ( &gt; 􏰁10 min) CPR
-   Major surgery ( &lt; 􏰂3 wk)
-   Recent (within 2 to 4 wk) internal bleeding
-   Noncompressible vascular punctures
-   Pregnancy
-   Active peptic ulcer
-   Oral anticoagulant therapy

## Post-ACS Chronic Therapies

-   Beta-blockers in pts w/o CIs
-   ACEIs / ARBs, esp in pts w/ LVEF &lt; 40%
-   High-Intensity Statins
-   NTG SL PRN



# References

[^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016.

[^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. *Journal of the American College of Cardiology*. 2014;64(24):e139-e228. doi:[10.1016/j.jacc.2014.09.017](https://doi.org/10.1016/j.jacc.2014.09.017)
[^dipiro]: DiPiro, JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education, 2017.
[^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019)
[^thygesen]: Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, and White, HD. Third Universal Definition of Myocardial Infarction.16.
[^smith2012-lbbb-stemi]: Smith, SW, Dodd, KW, Henry, TD, Dvorak, DM, and Pearce, LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine* 2012;60:766–776.
[^driver2017]: Driver, BE, Khalil, A, Henry, T, Kazmi, F, Adil, A, and Smith, SW. A New 4-Variable Formula to Differ- entiate Normal Variant ST Segment Elevation in V2-V4 (Early Repolarization) from Subtle Left Anterior Descending Coronary Occlusion - Adding QRS Amplitude of V2 Improves the Model. *Journal of Electrocardiology* 2017;50:561–569.
[^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.  Available at:  http://online.lexi.com.
